Clinical Trial Update: ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating discontinuation of ACE inhibitors or ARBs in patients with cardiovascular disease and SARS-CoV-2 infection; trial status terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Sars-cov-2 COVID-19 Infection

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection | Phase 3 | Status: TERMINATED